GeneSure PGS/PGD

GeneSure™ is Genea’s pre-implantation genetic testing and includes both Pre-implantation Genetic Diagnosis (PGD) and Pre-Implantation Genetic Screening (PGS). PGD and PGS involve testing embryos created in the IVF process for genetic abnormalities and helps detect the best possible embryo for transfer.

Amie and James had three miscarriages before turning to IVF for PGS. Hear their story

PGD and PGS explained

Highly trained and experienced scientists microscopically remove a few cells from the embryo and test the DNA. An embryo free of abnormalities is then transferred to the woman as part of the normal IVF process or remains frozen for future use. The difference between PGD and PGS is how and what they screen for.

PGD is often used by couples who don’t have an infertility issue but know they carry a serious genetic disorder, with the aim of having a child free of the disease. A genetic work up is required which involves blood samples from each partner and may require additional samples from other family members. This work up process ultimately enables scientists to identify all the affected and non-affected DNA patterns in the patient’s embryos. At Genea, we have experience with more than 230 genetic diseases as part of our PGD program so far. These conditions are often disabling, have no prevention, cure or proven treatments, beyond symptomatic care. For example, Duchenne muscular dystrophy, Huntington disease, Leigh’s disease and Fragile X. PGD also screens for cystic fibrosis which is the most common single gene disorder screened for at Genea.

PGS, is often used by couples who are older, have experienced recurrent miscarriage or have had a number of failed embryo transfers following IVF treatment. It doesn’t require a genetic work up but rather screens embryos to ensure they have the correct number and order of chromosomes.

PGS maximises patients’ potential to have a baby by reducing miscarriage rates* and increasing live birth rates*.

Genea PGS technology

PGS results are significant, particularly for women over the age of 38:

Genea PGS results graph

Get in touch with our Fertility Advisor

Genea Fertility has legal obligations to protect your personal information and to provide you with details about how we deal with this information. Please read our Privacy Policy and Collection Statement.


Frequently Asked Questions

PGD is used by couples who know they carry a serious genetic disorder, a genetic work-up is required and the embryos are tested for a specific abnormality. PGS is a full review of chromosome number and order and is used by couples who have experienced recurrent miscarriage, numerous failed embryo transfers and/or older patients. 

Embryos develop in the laboratory for five days until they reach what is called the blastocyst stage, before a biopsy is performed to remove a small number of cells for PGD/PGS screening.

Genea’s GeneSure technology uses preimplantation genetic screening to detect chromosomal abnormalities to select the best possible embryo for transfer - as a result of the technology, at Genea, we have seen a 50% decrease in miscarriage rate* and double the live birth rates*

*Per embryo transfer. Compared to standard IVF for women 38 years and over where the embryos are not tested for chromosomal abnormalities.

At Genea, we have experience with more than 230 genetic diseases as part of our PGD program so far. For example: Duchenne muscular dystrophy, Huntington disease, Leigh’s disease, Fragile X and cystic fibrosis. 

Genea has pioneered pre-implantation genetic testing, our expertise and techniques are amongst the best in the world. Many clinics have followed our lead and modelled their approach to embryo biopsy on ours. Genea is one of the very few clinics in Australia with the vital combination of IVF and genetics facilities to perform these sophisticated genetic screening tests successfully.